Immunovant's IMVT-1402 Hits ACR20 Endpoint in D2T RA; Sjogren's Program Shelved
IMVT sits 67% above its 52-week low of $21.43 on elevated volume (1.9× avg).
Summary
Immunovant's IMVT-1402 600 mg met the ACR20 primary endpoint in difficult-to-treat rheumatoid arthritis (92.5% vs 75.6% placebo), but the 300 mg dose failed and the company signaled it will likely stop Sjogren's development. Cash of $722.3M funds operations to a potential Graves' disease launch.
Key Events · Product Development and Regulatory · IMVT
-
IMVT-1402 Meets ACR20 Endpoint
In Period 2 of the potentially registrational D2T RA trial, 92.5% of patients on IMVT-1402 600 mg maintained an ACR20 response at Week 28 versus 75.6% on placebo (p=0.0139), across 117 randomized participants.
-
300 mg Dose Fails to Separate
The 300 mg arm showed 75.0% ACR20 response versus placebo, p=0.9426 — no difference — leaving the high dose as the only active arm and complicating the registrational strategy.
-
Sjogren's Program Effectively Shelved
Citing the evolving SjD landscape and recent field data, Immunovant said it is unlikely to advance IMVT-1402 beyond the ongoing, fully enrolled Phase 2 trial in Sjogren's disease.
-
FDA Talks Set for Later This Year
Discussions with the FDA are planned for later this year to determine the path forward for the D2T RA registrational program; GD and MG topline data are expected in 2027 and CIDP in 2028.
Analysis · IMVT · Life Sciences
The 600 mg dose of IMVT-1402 kept 92.5% of difficult-to-treat rheumatoid arthritis patients at an ACR20 response at Week 28 versus 75.6% on placebo (p=0.0139), the first randomized-withdrawal win for the program after the September CLE study failure. The catch is that the 300 mg arm showed no separation from placebo (75.0%, p=0.9426), so the registrational path depends on convincing the FDA that the high dose alone is approvable — discussions are planned for later this year. Management also conceded it is unlikely to push IMVT-1402 further in Sjogren's disease beyond the fully enrolled Phase 2 trial, narrowing the label opportunity. With $722.3M in cash and a $97.2M quarterly net loss, funding reaches a potential Graves' disease launch, and GD and MG topline data in 2027 are the next binary readouts.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 47.1% of the 1533 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IMVT was trading at $35.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.3B. The 52-week trading range was $21.43 to $45.42. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.